On Thursday, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)’s shares declined -0.08% to $61.99.
ISIS Pharmaceuticals, Inc. (ISIS) offered an update on children with spinal muscular atrophy (SMA) who have accomplished the open-label, Phase 2 multiple-dose study of ISIS-SMNRx and are ongoing to receive treatment in an open-label extension (OLE) study. Compriseent with earlier observations, enhances in muscle function scores and additional motor function tests were observed in children treated with ISIS-SMNRx. Isis is presently collaborating with Biogen to develop and commercialize ISIS-SMNRx to treat patients with SMA.
In the OLE study, a total of 30 children with Type II or Type III SMA received 12 mg of ISIS-SMNRx dosed intrathecally every six months. Children who enrolled in the OLE study had accomplished the open-label Phase 2 study of ISIS-SMNRx in which they had received multiple doses of either 3 mg, 6 mg, 9 mg, or 12 mg of ISIS-SMNRx. Clinical endpoints were measured every three months and contrast to each patient’s Phase 2 baseline score. These endpoints comprised of measurements of muscle function using the Hammersmith Functional Motor Scale-Expanded (HFMSE), the six minute walk test (6MWT) for ambulatory patients and the upper limb module (ULM) test for non-ambulatory patients.
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, which include neurological disorders; and cancer.
Intuit Inc. (NASDAQ:INTU)’s shares gained 0.53% to $103.60.
Intuit Inc. (INTU) QuickBooks Connect is returning to San Jose, Calif., with notable names joining the main stage lineup, counting The Honest Company’s Jessica Alba, founder and chief creative officer, and Brian Lee, co-founder and chief executive officer, in addition to Sekou Andrews, entrepreneur and poetic motivational speaker. Intuit QuickBooks will present these and other speakers with the aim of inspiring attendees and sharing lessons for small business success. Attendees can register at www.QuickBooksConnect.com.
Taking place Nov. 2-4, QuickBooks Connect will unite thousands of entrepreneurs, small businesses, accountants and developers under one roof to get connected, educated and inspired via hands-on breakout sessions, engaging main stage presentations and unique networking opportunities. Building on the success of last year’s event, QuickBooks Connect will feature a dynamic agenda and experience designed to assist attendees’ businesses grow and succeed. Alba, Lee, Andrews and others yet to be declared will speak on Nov. 3 during the main stage event.
Intuit Inc. provides business and financial administration solutions for small businesses, consumers, and accounting professionals in the United States, Canada, the United Kingdom, Australia, India, and Singapore. The company’s Small Business segment provides QuickBooks financial and business administration online services and desktop software; QuickBooks technical support services; financial supplies; and small business payroll products and services.
At the end of Thursday’s trade, Lululemon Athletica inc. (NASDAQ:LULU)‘s shares surged 0.21% to $67.56.
Lululemon Athletica inc. (LULU) declared that Miguel Almeida has been named as Executive Vice President, Digital, effective as of the start of his employment with the Company, which is expected to be mid-July. He will report to the Company’s Chief Executive Officer, Laurent Potdevin.
Mr. Almeida’s career spans over 15 years of operational and senior leadership with a keen focus on digital strategies. Most recently, he was the Group VP, Digital Commerce and Mobile solutions for Walgreens where he was responsible for omni-channel initiatives, mobile solutions, and online-to-consumer commerce across a variety of digital brands. Prior to joining Walgreens, Miguel held senior roles in the online groups of Apple and Dell where he drove global online expansion for both companies. Formerly, he was a strategy consultant with The Boston Consulting Group where he worked across multiple countries in Europe and South America mainly in high technology, telecom, ecommerce, marketing and retail.
lululemon athletica inc., together with its auxiliaries, designs, manufactures, and distributes athletic apparel and accessories for women, men, and female youth. It operates through two segments, Corporate-Owned Stores and Direct To Consumer. The company offers pants, shorts, tops, and jackets for healthy lifestyle activities and athletic pursuits, such as yoga, running, and general fitness; and dance-inspired apparel for female youth.
Dollar Tree, Inc. (NASDAQ:DLTR), ended its Thursday’s trading session with -0.14% loss, and closed at $80.46.
Dollar Tree, Inc. (DLTR) an operator of discount variety stores offering merchandise at a fixed price point of $1.00, seems to have a compelling growth story given its progress on the back of endeavors, including store expansion, omni-channel development and penetration into new markets.
However, the stock was let down by its performance in first-quarter fiscal 2015, wherein both top and bottom lines missed the Zacks Consensus Estimate, as sales were hurt by an unfavorable shift in Easter holiday timing and labor disruptions at the West Coast port. Also, the company had to pay incremental freight costs on account of alternate ports.
These headwinds triggered management to tweak its outlook for the fiscal, following which the stock witnessed downward estimate revisions.
Dollar Tree now anticipates sales for the fiscal to be in the range of $9.24–$9.42 billion, contrast with $9.21–$9.45 billion predicted earlier, based on the expectation that comps will grow in a low to low-mid single-digit range in fiscal 2015. Moreover, the company now envisions adjusted earnings per share for fiscal 2015 to be in the band of $3.32–$3.47 contrast with $3.30–$3.50 projected earlier.
Dollar Tree, Inc. operates discount variety stores in the United States and Canada. Its stores offer merchandise at the fixed price of $1.00. The company’s stores provide consumable merchandise, which comprises candy and food, and health and beauty care products; and everyday consumables, such as paper and chemicals, and frozen and refrigerated food. Its stores also offer various merchandise that comprise toys, durable housewares, gifts, party goods, greeting cards, softlines, and other items; and seasonal goods comprising of Valentine’s Day, Easter, Halloween, and Christmas merchandise.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s shares gained 3.85% to $2.97.
As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS). The stock has moved higher by 9.1% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. This might be the case, particularly if you consider SNSS’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as SNSS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has accomplished a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
